Thrombotic Thrombocytopenic Purpura, Acquired News

Thrombotic Thrombocytopenic Purpura, Acquired	Welcome, Profile Billing Logout

||||||||||  danazol oral / Generic mfg.
Enrollment change:  Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP) (clinicaltrials.gov) -  Jan 5, 2024
P2, N=9, Terminated,  Sponsor: Icahn School of Medicine at Mount Sinai
N=29 --> 9

||||||||||  prednisone / Generic mfg., cyclosporin A microemulsion / Generic mfg., hydrocortisone / Generic mfg.
Enrollment change:  Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP) (clinicaltrials.gov) -  Apr 28, 2023
P3, N=26, Completed,  Sponsor: Ohio State University
N=29 --> 9 N=16 --> 26

||||||||||  danazol oral / Generic mfg.
Enrollment change, Trial termination:  Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP) (clinicaltrials.gov) -  Dec 10, 2018
P2, N=8, Terminated,  Sponsor: Icahn School of Medicine at Mount Sinai
N=16 --> 26 N=25 --> 8 | Recruiting --> Terminated; low enrollment

||||||||||  prednisone / Generic mfg., cyclosporin A microemulsion / Generic mfg., hydrocortisone / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date:  Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP) (clinicaltrials.gov) -  Sep 25, 2017
P3, N=16, Completed,  Sponsor: Ohio State University
N=25 --> 8 | Recruiting --> Terminated; low enrollment Active, not recruiting --> Completed | N=62 --> 16 | Trial primary completion date: Jun 2017 --> Sep 2017

||||||||||  prednisone / Generic mfg., cyclosporin A microemulsion / Generic mfg., hydrocortisone / Generic mfg.
Trial primary completion date:  Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP) (clinicaltrials.gov) -  Jan 17, 2017
P3, N=62, Active, not recruiting,  Sponsor: Ohio State University
Active, not recruiting --> Completed | N=62 --> 16 | Trial primary completion date: Jun 2017 --> Sep 2017 Trial primary completion date: Oct 2016 --> Jun 2017

||||||||||  prednisone / Generic mfg., cyclosporin A microemulsion / Generic mfg., hydrocortisone / Generic mfg.
Trial primary completion date:  Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP) (clinicaltrials.gov) -  Sep 28, 2016
P3, N=62, Active, not recruiting,  Sponsor: Ohio State University
Trial primary completion date: Oct 2016 --> Jun 2017 Trial primary completion date: Aug 2017 --> Oct 2016

|||||||||| Enrollment change, Trial initiation date, Trial primary completion date, Head-to-Head: Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP) (clinicaltrials.gov) - Nov 22, 2015
P3, N=8, Terminated, Sponsor: Octapharma
Trial primary completion date: Aug 2017 --> Oct 2016 N=112 --> 8 | Initiation date: Dec 2006 --> May 2007 | Trial primary completion date: May 2008 --> Feb 2008

||||||||||  danazol oral / Generic mfg.
Trial primary completion date:  Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP) (clinicaltrials.gov) -  Jul 20, 2015
P2, N=25, Recruiting,  Sponsor: Beth Israel Medical Center
N=112 --> 8 | Initiation date: Dec 2006 --> May 2007 | Trial primary completion date: May 2008 --> Feb 2008 Trial primary completion date: Dec 2015 --> Dec 2020

||||||||||  prednisone / Generic mfg., cyclosporin A microemulsion / Generic mfg., hydrocortisone / Generic mfg.
Enrollment closed:  Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP) (clinicaltrials.gov) -  Apr 22, 2015
P3, N=62, Active, not recruiting,  Sponsor: Ohio State University
Trial primary completion date: Dec 2015 --> Dec 2020 Recruiting --> Active, not recruiting

||||||||||  danazol oral / Generic mfg.
Trial primary completion date:  Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP) (clinicaltrials.gov) -  Dec 30, 2014
P2, N=25, Recruiting,  Sponsor: Beth Israel Medical Center
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2014 --> Dec 2015

||||||||||  prednisone / Generic mfg., cyclosporin A microemulsion / Generic mfg., hydrocortisone / Generic mfg.
Trial primary completion date:  Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP) (clinicaltrials.gov) -  Aug 15, 2014
P3, N=62, Recruiting,  Sponsor: Ohio State University
Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Nov 2015 --> Aug 2017

||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment change:  PTTritux: Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura (clinicaltrials.gov) -  Feb 25, 2014
P2, N=12, Completed,  Sponsor: Assistance Publique - H
Trial primary completion date: Nov 2015 --> Aug 2017 N=10 --> 12

||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion:  PTTritux: Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura (clinicaltrials.gov) -  Feb 25, 2014
P2, N=12, Completed,  Sponsor: Assistance Publique - H
N=10 --> 12 Active, not recruiting --> Completed

|||||||||| Trial termination: International Registry and Biorepository for TMA(Thrombotic Microangiopathy) (clinicaltrials.gov) - Jun 17, 2013
P=N/A, N=6, Terminated, Sponsor: North Shore Long Island Jewish Health System
Active, not recruiting --> Completed Enrolling by invitation --> Terminated; study stopped at this site, as investigator left the institution

|||||||||| Enrollment change: International Registry and Biorepository for TMA(Thrombotic Microangiopathy) (clinicaltrials.gov) - Jun 17, 2013
P=N/A, N=6, Terminated, Sponsor: North Shore Long Island Jewish Health System
Enrolling by invitation --> Terminated; study stopped at this site, as investigator left the institution N=60 --> 6

|||||||||| Trial withdrawal: PLEX-RCT: The Plasma Large-Volume Exchange RCT (clinicaltrials.gov) - Apr 15, 2013
P3, N=0, Withdrawn, Sponsor: London Health Sciences Centre
N=60 --> 6 Not yet recruiting --> Withdrawn

|||||||||| Enrollment change: PLEX-RCT: The Plasma Large-Volume Exchange RCT (clinicaltrials.gov) - Apr 15, 2013
P3, N=0, Withdrawn, Sponsor: London Health Sciences Centre
Not yet recruiting --> Withdrawn N=150 --> 0

|||||||||| New P4 trial: Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura (clinicaltrials.gov) - Dec 19, 2012
P4, N=0, Withdrawn, Sponsor: St. Olavs Hospital

||||||||||  Rituxan (rituximab) / Roche
Trial withdrawal:  Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura (clinicaltrials.gov) -  Nov 13, 2012
P1/2, N=0, Withdrawn,  Sponsor: Weill Medical College of Cornell University
N=150 --> 0 Completed --> Withdrawn

||||||||||  Rituxan (rituximab) / Roche
Enrollment change:  Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura (clinicaltrials.gov) -  Nov 13, 2012
P1/2, N=0, Withdrawn,  Sponsor: Weill Medical College of Cornell University
Completed --> Withdrawn N=12 --> 0

|||||||||| New P3 trial: PLEX-RCT: The Plasma Large-Volume Exchange RCT (clinicaltrials.gov) - Sep 11, 2011
P3, N=0, Withdrawn, Sponsor: London Health Sciences Centre



	Diseases Companies Products Productz Mechanisms of Action Sites